76.45 
0.88(1.14%) 4:03PM EDT
| Prev Close: | 77.33 |
|---|
| Open: | 77.15 |
|---|
| Bid: | 72.11 x 700 |
|---|
| Ask: | 80.63 x 600 |
|---|
| 1y Target Est: | 73.85 |
|---|
| Beta: | 1.02 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | 76.31 - 77.38 |
|---|
| 52wk Range: | 44.19 - 78.36 |
|---|
| Volume: | 161,136 |
|---|
| Avg Vol (3m): | 389,795 |
|---|
| Market Cap: | 4.27B |
|---|
| P/E (ttm): | 39.53 |
|---|
| EPS (ttm): | 1.93 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- [video] Covance Not Cooling Offat TheStreet(Fri, May 17)
- Cramer: This Fresh-Faced IPO Still a Buyat CNBC(Mon, May 13)
- Covance To Present At The Bank Of America Merrill Lynch 2013 Health Care ConferencePR Newswire(Mon, May 13)
- COVANCE INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of SecuritEDGAR Online(Mon, May 13)
- COVANCE INC FinancialsEDGAR Online Financials(Fri, May 10)
- Quintiles Climbs 5% In Debut In A Busy Day, Week For IPOsInvestor's Business Daily(Thu, May 9)
- Quintiles IPO Cleans Up As New Issues Multiplyat Investor's Business Daily(Thu, May 9)
- Quintiles shares rise 11 percent in market debutat Reuters(Thu, May 9)
- Pharmaceutical services provider Quintiles surges on first day of tradingat theflyonthewall.com(Thu, May 9)
- Quintiles IPO raises more-than-planned $947 mln as stocks rallyat Reuters(Wed, May 8)
- The Next Billionaire: A Statistician Who Changed Medicineat Forbes(Wed, May 8)
- Covance To Present At The R. W. Baird 2013 Growth Stock ConferencePR Newswire(Mon, May 6)
- Covance Beats Earnings, Rev, Ups ViewZacks(Mon, May 6)
- COVANCE INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 3)
- Covance Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 2)
Key Statistics
| Forward P/E (1 yr): | 20.77 |
|---|
| P/S (ttm): | 1.94 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 3.13 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.77 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | 1.71 |
|---|
Business Summary
Covance Inc., a drug development services company, provides various early-stage and late-stage product development services primarily to the pharmaceutical, biotechnology, and medical device industries primarily in the United States and Europe.
View More